Kommanditgesellschaft auf Aktien

(redirected from KGaA)
Also found in: Acronyms, Wikipedia.

Kommanditgesellschaft auf Aktien

Abbreviated KgAA. A corporate structure in Germany equivalent to a master limited partnership.
References in periodicals archive ?
Despite seeing signs of activity in pancreatic cancer, pre-specified primary endpoints were not met in both studies and therefore the data do not support filing in these indications," said Luciano Rossetti, Head of Global Research and Development at the biopharma business of Merck KGaA, Darmstadt, Germany.
Siegwerk produced the respective pearlescent inks with pigments from Merck KGaA.
We continue to explore opportunities that will allow us to better understand the potential ADCs have in directly targeting cancer cells, said Andree Blaukat, Senior Vice President and Head of Translational Innovation Platform Oncology at Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.
Merck KGaA, Darmstadt, Germany, ranked highly across the categories of social responsibility, having loyal employees, and having a work culture aligned with employees' values.
But, Merck KGaA didn t reveal the financial terms of this deal, which is likely to be completed in Q2 of 2012.
As one of the Merck, KGaA, Darmstadt, Germany operating companies in North America, it has been difficult for us to communicate to our customers and the market exactly who and how strong a global organization we really are," he continued.
Merck KGaA worked constructively with the FDA and other health authorities to address the questions raised on the safety of BLP25 liposome vaccine in patients with NSCLC and, as a result, we can now resume our NSCLC clinical program," commented Dr.
We are honored to have Laszlo join Merck KGaA, Darmstadt, Germany," said Luciano Rossetti, Head of Global Research and Development.
Provides all the crucial information on Hella KGaA Hueck & Co.
Kashdan partnered with Merck KGaA, Darmstadt, Germany to analyze the State of Curiosity findings.
The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux([R])) in second-line cetuximab-naove patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
In the news release, Merck KGaA, Darmstadt, Germany Presents First Curiosity Report in the U.